Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease

The advent of anti-tumor necrosis factor (TNF)-α therapy has been a major advance in the medical management of Crohn's disease (CD). However, a significant proportion of patients with CD do not respond adequately to treatment with these agents. Primary and secondary nonresponse to anti-TNFα the...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental gastroenterology 2014-01, Vol.7 (default), p.173-179
Main Authors: Tuskey, Anne, Behm, Brian W
Format: Article
Language:English
Subjects:
Arthritis
Clinical trials
Crohn's disease
Cytokines
Drug therapy
Gastroenterology
Health aspects
Lymphocytes
Medical research
Monoclonal antibodies
Patient outcomes
Pharmacokinetics
Population
Psoriasis
Quality of life
R&D
Research & development
Review
Tumor necrosis factor-TNF
Ustekinumab
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The advent of anti-tumor necrosis factor (TNF)-α therapy has been a major advance in the medical management of Crohn's disease (CD). However, a significant proportion of patients with CD do not respond adequately to treatment with these agents. Primary and secondary nonresponse to anti-TNFα therapy represents a common clinical challenge, and highlights the need for the development of additional medication options for CD. The proinflammatory cytokines interleukin (IL)-12 and IL-23 are thought to play a key role in the pathogenesis of CD, and serve as a potential target for additional biologic therapies. Monoclonal antibodies targeting IL-12/23 have shown efficacy in animal models of colitis, and are currently being studied in Phase III clinical trials of CD. This review focuses on ustekinumab, a fully human immunoglobulin G1 monoclonal antibody, which blocks activity of IL-12 and IL-23 through binding the p40 subunit, and describes the current efficacy and safety data for ustekinumab in patients with CD.
ISSN:1178-7023
1178-7023
DOI:10.2147/CEG.S39518